ESR1 and breast carcinoma: Clinically, sulforaphane in a placebo-controlled, double-blinded, randomized design of a population of postmenopausal breast cancer patients, most of whom had an early-stage breast cancer (I/II) that was predominantly ER+, and HER2- indicated a decline in Ki-67 (cell proliferation), yet no biomarkers were statistically significant.